Jefferies on Sarepta Therapeutics (SRPT): 'The risk/reward seems favorable'
Tweet Send to a Friend
Jefferies analyst Yun Zhong reiterated a Buy rating and $30.00 price target on Sarepta Therapeutics (NASDAQ: SRPT).The analyst comments "The ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
